Navigation Links
Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
Date:11/9/2007

Oral Presentation by Dr. Robert Figlin Highlights Phase 2 Data Showing 31% Partial Response Rate and a 62% Overall Clinical Benefit Rate to Perifosine Used as a Single Agent and Phase 1 Data Showing No Evidence of Increased

Toxicity When Combined with Sorafenib

NEW YORK, Nov. 9 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. today announced positive phase 1 & 2 data of perifosine (KRX-0401) in patients with advanced renal cell carcinoma (RCC). In an oral presentation entitled "PERIFOSINE: AN ORAL, AKT INHIBITOR WITH CLINICAL ACTIVITY IN ADVANCED RENAL CELL CARCINOMA," Dr. Robert Figlin, Medical Oncology Chair and Professor of Medicine, City of Hope National Medical Center in Duarte, CA provided an update on the clinical activity of single agent perifosine from a phase 2 trial (Protocol 207), and reported on the safety and efficacy of perifosine in combination with sorafenib from an ongoing phase I study (Protocol 124).

Phase 2 Single Agent in RCC - Protocol 207

Twenty-four patients with advanced renal cell carcinoma (RCC) were randomized to either the daily (50 mg or 100mg) or weekly (900mg or 1200mg) dose of perifosine. Patients with measurable disease who received at least 2 courses of perifosine and at least one tumor measurement after initiation of perifosine, were considered evaluable for response using RECIST criteria. Thirteen were evaluable for response. Four of these (31%) had a partial response and an additional 4 patients (31%) achieved long-term stable disease for a 62% overall clinical benefit rate. Five patients progressed. One of the responding patients had previously failed to respond to both sorafenib and sunitinib. The results are as follows:

50 1200

or or

100 mg 900 mg

Protocol 207
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Reportlinker.com announces that a new ... Germany Aesthetic Lasers and Energy Devices ... http://www.reportlinker.com/p02343442/Germany-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html Germany Aesthetic Lasers and ... GlobalData,s new report, "Germany Aesthetic Lasers and ... market data on the Germany Aesthetic Lasers and ...
(Date:8/28/2014)... N.J. , Aug. 28, 2014 /PRNewswire-iReach/ -- ... medical device space, is excited to announce they ... the VIEW Plating System and REDUCE Fracture Plating ... anatomic plates used to support multiple indications within ... packaged Lapidus, First Metatarsophalangeal (MTP), Calcaneal-Cuboid (CC), Talonavicular ...
(Date:8/28/2014)... Aug. 28, 2014 /PRNewswire-iReach/ -- Academy Leadership, an elite ... graduates, has published a case study highlighting ... Excellence Course . In September and October 2014, Academy ... to Albuquerque , Indianapolis , Salt ... Photo - http://photos.prnewswire.com/prnh/20140828/140814 Leadership ...
Breaking Medicine Technology:Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 9EDGE Orthopaedics Receives Second FDA Clearance 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
(Date:8/28/2014)... American adults who are beginning to ... will now have a simpler way to connect with ... this year, some of the best life insurance rates ... , The promoted plans that included price data revealed ... popular policies. The term, guaranteed and modified plans that ...
(Date:8/28/2014)... York (PRWEB) August 28, 2014 ... bellwether trial of a transvaginal mesh lawsuit ( ... Inc., Bernstein Liebhard LLP reports. Court documents pending ... West Virginia indicate that the case was filed ... undergo two revision surgeries, allegedly due to vaginal ...
(Date:8/28/2014)... Vernon, Ind. (PRWEB) August 28, 2014 ... of Valero Energy Corporation (NYSE: VLO), and the Ports ... state and local officials today at a Port Appreciation ... purchased Mount Vernon ethanol plant. , “The opening of ... Vernon is another economic development win for the ...
(Date:8/28/2014)... take wing? Did they fall from trees and learn to ... along the ground and pump their "arms" to get aloft? ... past, but a new University of California, Berkeley, study provides ... ability to maneuver in midair, a talent that could have ... a perch. , The study looked at how baby birds, ...
(Date:8/28/2014)... of Medicine published research results on Aug. 21 ... safely reduce the viral load and clinical illness of ... (RSV). , Le Bonheur Children,s Hospital and ... Disease Specialist John DeVincenzo, MD, is lead author of ... common cause of lower respiratory tract infections in young ...
Breaking Medicine News(10 mins):Health News:Best Life Insurance Rates for 2014 Now Promoted at Insurer Website 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 2Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 3Health News:Flapping baby birds give clues to origin of flight 2Health News:Flapping baby birds give clues to origin of flight 3Health News:DeVincenzo study breakthrough in RSV research 2
... will save lives this holiday season, NEW ... Friday" and the holiday season, New York Blood ... the children and,families whose lives are stricken by ... survival. Among these diseases are: Leukemia,and other forms ...
... efforts through second Innovation Event, INDIANAPOLIS, ... WLP ), the,nation,s largest health insurance company ... will begin accepting applications for its second ... innovation,partnership efforts by providing an accelerated process ...
... lead to vaccine that works , , THURSDAY, Nov. 13 (HealthDay ... has failed, but researchers report that they,ve still gained insight ... "It,s raised a whole new set of questions that are ... to a successful vaccine," said Dr. Susan P. Buchbinder, lead ...
... ... hospitals, ... announced HealthBIT, a healthcare business intelligence platform for,hospitals. HealthBIT(TM) provides ... and comparing their,data to provide actionable opportunities that result in ...
... shows economic,stress takes toll on the emotional and ... conducted by the American Psychological Association, shows,at least ... economy as their top,stressors. More than half, reported ... anger. Forty-six percent indicated they,were worried about providing ...
... options dwindle or are exhausted, terminally ill-patients often ... therapies. However, a team of researchers from Wake ... Medical Center and Unity Health System, report that ... governing end-of-life care may be leaving many medical ...
Cached Medicine News:Health News:A Thanksgiving Message From New York Blood Center 2Health News:A Thanksgiving Message From New York Blood Center 3Health News:WellPoint Announces Second Annual Innovation Event 2Health News:WellPoint Announces Second Annual Innovation Event 3Health News:HIV Vaccine Failure Still Brings Insights 2Health News:Sentry Data Systems Announces Healthcare Business Intelligence Technology Platform 2Health News:Economic Stress Takes Toll on Health 2Health News:Doctors' questions about end-of-life legalities may result in patient pain 2Health News:Doctors' questions about end-of-life legalities may result in patient pain 3
For the quantitative in vitro determination of CK-MB in serum and plasma...
The ALT method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of alanine aminotransferase activity in serum or plasma....
For the quantitative in vitro determination of Alanine Aminotransferase (ALT) in serum and plasma....
... S-1™ Biodegradable Anteroir Cervical System, in conjunction ... with a collar), is intended for use ... fusion procedures as a means to maintain ... or autografts., This device is not intended ...
Medicine Products: